Latest Health News
WHO and ProMED report multiple infectious disease outbreaks worldwide
ProMED and regional surveillance are flagging increased reports of avian influenza (H5N1) in poultry and sporadic human exposures in Asia, foodborne outbreaks in India, and rising tetanus cases in the United States tied to falling vaccination rates; ProMED’s daily alerts list multiple incidents and regional updates supporting heightened vigilance.
Stanford identifies mechanism for rare myocarditis after mRNA COVID vaccines
Stanford researchers reported how mRNA COVID‑19 vaccines can very rarely trigger heart inflammation in young men and proposed insights that could reduce that risk, providing a mechanistic explanation for a rare safety signal following vaccination.
2025 saw multiple pivotal FDA oncology approvals—continuing impact into year‑end
The FDA’s 2025 approvals included several targeted therapies and ADCs for lung and other cancers (for example, ADCs targeting TROP2 and c‑Met and new TKIs), reshaping precision treatment pathways and requiring broader molecular profiling in oncology practice.
FDA authorizes novel gene and cell therapies including first treatment for MacTel
The FDA approved Encelto, the first therapy for macular telangiectasia type 2, and granted breakthrough designations for other gene approaches (e.g., AMT‑130 for Huntington disease), marking major progress in gene/cell therapy regulation and clinical translation in 2025.
RNAi expands into cardiomyopathy with Amvuttra approval for ATTR‑CM
Alnylam’s vutrisiran (Amvuttra) received FDA approval for transthyretin‑mediated cardiomyopathy (ATTR‑CM), showing reductions in cardiovascular death/events and expanding RNA‑based therapeutics into cardiac disease management.
New AI findings: diagnostic tools show unexpected demographic inference risks
Research revealed that AI systems trained to detect cancer from pathology slides can inadvertently learn and infer patient demographic information, raising privacy and bias concerns for clinical AI deployment.
Breakthroughs in in vivo tissue 3D printing and compact gene editors accelerate regenerative medicine
Work in 2025 demonstrated in‑body 3D bioprinting (DISP) and the development of a much smaller CRISPR variant (NanoCas), advancing possibilities for minimally invasive tissue engineering and broader in‑body gene editing delivery.
Alzheimer’s early‑stage therapeutic candidate shows promise in preclinical studies
A new experimental drug (referred to as NU‑9 in reporting) was reported to block early toxic protein activity and inflammation in mouse models, suggesting potential for preventing Alzheimer’s before clinical memory loss emerges, though human data remain pending.
Regulatory updates broaden menopause and psychiatric treatment options
Late‑2025 product updates include approvals of new agents such as elinzanetant for menopause vasomotor symptoms and lumateperone formulations for depression, reflecting ongoing expansion of therapeutic choices in women’s health and psychiatry.
Public‑health surveillance notes seasonal and climate‑linked shifts in vaccine‑preventable diseases
Reports highlight increases in tetanus and other vaccine‑preventable infections tied in part to declining immunization coverage and climate‑related disruptions, prompting calls for strengthened vaccination programs and surveillance.
CAR‑T and cell therapies show progress against solid tumors in preclinical and early clinical studies
Preclinical studies in 2025 reported CAR‑T constructs capable of shrinking metastasized solid tumors in animal models and spurred plans for translation to human trials, indicating momentum in adapting cell therapy to solid cancers.
FDA oncology approvals emphasize need for comprehensive molecular testing in cancer care
Multiple 2025 oncology approvals (including targeted agents for KRAS G12C, HER2, ROS1, and others) underscore the clinical imperative for expanded molecular profiling at diagnosis and progression to guide therapy selection.